Pacira Pharmaceuticals buy Truist Financial Co.
Start price
25.07.25
/
50%
€18.90
Target price
25.07.26
€25.55
Performance (%)
-2.65%
Price
15.01.26
€19.00
Summary
This prediction is currently active. With a performance of -2.65%, the BUY prediction for Pacira Pharmaceuticals by Truist_Financial_Co_ is down slightly. This prediction currently runs until 25.07.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | -14.414% | -14.414% |
| iShares Core DAX® | 0.336% | 4.366% |
| iShares Nasdaq 100 | 0.541% | 3.170% |
| iShares Nikkei 225® | 4.048% | 6.727% |
| iShares S&P 500 | 0.795% | 3.281% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at Truist Financial Corporation from a "hold" rating to a "buy" rating. They now have a $30.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€19.10
07.11.25
07.11.25
€24.27
07.11.26
07.11.26
-3.14%
15.01.26
15.01.26
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€18.40
25.07.24
25.07.24
€27.62
25.07.25
25.07.25
2.17%
26.07.25
26.07.25